No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance

Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated...

Full description

Saved in:
Bibliographic Details
Published inJournal of thrombosis and haemostasis Vol. 13; no. 4; pp. 592 - 600
Main Authors Groeneveld, D. J., Bekkum, T., Cheung, K. L., Dirven, R. J., Castaman, G., Reitsma, P. H., Vlijmen, B., Eikenboom, J.
Format Journal Article
LanguageEnglish
Published England Elsevier Limited 01.04.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. Objectives To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Methods Three type 3 von Willebrand disease (VWD) patients were infused with Haemate‐P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF‐deficient mice were injected with purified plasma‐derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. Results In mice, we found no difference in clearance rate between plasma‐derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate‐P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two‐fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. Conclusion There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non‐blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.
AbstractList One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated.BACKGROUNDOne of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated.To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF.OBJECTIVESTo determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF.Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O.METHODSThree type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O.In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient.RESULTSIn mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient.There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.CONCLUSIONThere is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.
Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. Objectives To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Methods Three type 3 von Willebrand disease (VWD) patients were infused with Haemate‐P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF‐deficient mice were injected with purified plasma‐derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. Results In mice, we found no difference in clearance rate between plasma‐derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate‐P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two‐fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. Conclusion There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non‐blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.
Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. Objectives To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Methods Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. Results In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. Conclusion There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.
One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.
Author Dirven, R. J.
Groeneveld, D. J.
Cheung, K. L.
Eikenboom, J.
Bekkum, T.
Castaman, G.
Reitsma, P. H.
Vlijmen, B.
Author_xml – sequence: 1
  givenname: D. J.
  surname: Groeneveld
  fullname: Groeneveld, D. J.
  organization: Leiden University Medical Center
– sequence: 2
  givenname: T.
  surname: Bekkum
  fullname: Bekkum, T.
  organization: Leiden University Medical Center
– sequence: 3
  givenname: K. L.
  surname: Cheung
  fullname: Cheung, K. L.
  organization: Leiden University Medical Center
– sequence: 4
  givenname: R. J.
  surname: Dirven
  fullname: Dirven, R. J.
  organization: Leiden University Medical Center
– sequence: 5
  givenname: G.
  surname: Castaman
  fullname: Castaman, G.
  organization: Careggi University Hospital
– sequence: 6
  givenname: P. H.
  surname: Reitsma
  fullname: Reitsma, P. H.
  organization: Leiden University Medical Center
– sequence: 7
  givenname: B.
  surname: Vlijmen
  fullname: Vlijmen, B.
  organization: Leiden University Medical Center
– sequence: 8
  givenname: J.
  surname: Eikenboom
  fullname: Eikenboom, J.
  organization: Leiden University Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25650553$$D View this record in MEDLINE/PubMed
BookMark eNp90UFPIyEUB3CycbNV14NfwJB4cPdQhaEww1GNu11j3EsTjxMKj0pDocJMjd9euq0eGl0uD5LfewH-B2gvxAAIHVNyTsu6mHeP57RqRP0F7VPOmmHdMLH3tpeMDdBBznNCqOQV-YYGFReccM720eo-Ylg5A0EDtjFhhY1LoDsM1q5LtHgVA35w3sM0qWCwVbqL6Szjy6sxnvoYDZ6l2C-xCp2bQci4-A97sPagylnDd_TVKp_haFsP0eTXzeR6PLz7-_vP9eXdULOmqYcVleV9vJGVAqG0HkkCnGltuTRgOKGGwVQbyyopa6gKgVpXbKStoaQR7BD92IxdpvjUQ-7ahcsavFcBYp9bKoQcjWrOm0JPd-g89imUy61VXYwQvKiTreqnCzDtMrmFSi_t24cW8HMDdIo5J7DvhJJ2HVZbwmr_hVXsxY7VrlOdi6FLyvn_dTw7Dy-fj25vJ-NNxyus56T1
CitedBy_id crossref_primary_10_1161_JAHA_121_024581
crossref_primary_10_1182_bloodadvances_2021005928
crossref_primary_10_1111_bjh_15565
crossref_primary_10_1182_blood_2016_04_709436
crossref_primary_10_1016_j_jhep_2019_09_030
crossref_primary_10_1016_j_thromres_2020_11_016
crossref_primary_10_1111_jth_14304
crossref_primary_10_3233_BIR_15061
crossref_primary_10_1111_jth_13401
crossref_primary_10_12688_f1000research_13056_1
crossref_primary_10_1111_jth_14444
crossref_primary_10_1111_jth_14521
crossref_primary_10_1111_jth_13537
crossref_primary_10_1182_blood_2016_11_750885
crossref_primary_10_1182_blood_2020005843
crossref_primary_10_1111_jth_13294
Cites_doi 10.1182/blood-2006-04-015065
10.1172/JCI26007
10.1146/annurev.biochem.67.1.395
10.1111/j.1538-7836.2006.02273.x
10.1182/blood.V69.6.1691.1691
10.1074/jbc.M010805200
10.1182/blood-2013-01-479527
10.1159/000054087
10.1182/blood-2005-02-0792
10.1074/jbc.M310436200
10.1111/j.1537-2995.2006.00975.x
10.1111/j.1538-7836.2003.00435.x
10.1172/JCI107471
10.1161/hq0202.103997
10.1046/j.1538-7836.2003.00359.x
10.1160/TH06-09-0549
10.1089/hum.2008.089
10.1055/s-0038-1665305
10.1111/j.1538-7836.2007.02588.x
10.1016/S0021-9258(19)50338-6
10.1172/JCI108846
10.1371/journal.ppat.1002942
10.1111/jth.12226
10.1182/blood-2012-09-455089
10.1182/blood.V88.5.1692.1692
10.1182/blood-2007-11-122945
10.1182/blood.V88.8.2951.bloodjournal8882951
10.1111/j.1538-7836.2009.03453.x
ContentType Journal Article
Copyright 2015 International Society on Thrombosis and Haemostasis
2015 International Society on Thrombosis and Haemostasis.
Copyright © 2015 International Society on Thrombosis and Haemostasis
Copyright_xml – notice: 2015 International Society on Thrombosis and Haemostasis
– notice: 2015 International Society on Thrombosis and Haemostasis.
– notice: Copyright © 2015 International Society on Thrombosis and Haemostasis
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
DOI 10.1111/jth.12867
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7836
EndPage 600
ExternalDocumentID 3640738681
25650553
10_1111_jth_12867
JTH12867
Genre article
Journal Article
Comparative Study
GroupedDBID ---
05W
1OC
24P
29L
2WC
31~
33P
36B
3SF
4.4
52U
52V
53G
5GY
5VS
66C
8-0
8-1
A00
AAESR
AAEVG
AAHHS
AALRI
AAONW
AASGY
AAXRX
AAXUO
AAZKR
ABCUV
ABDBF
ABJNI
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADVLN
ADXAS
ADZMN
AEEZP
AEIMD
AENEX
AEQDE
AFBPY
AFEBI
AFGKR
AFJKZ
AFPWT
AFZJQ
AHMBA
AIACR
AITUG
AIURR
AIWBW
AJAOE
AJBDE
AKRWK
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMRAJ
AMYDB
ATUGU
AZBYB
AZVAB
BAWUL
BHBCM
BMXJE
BOGZA
BRXPI
C45
CAG
COF
CS3
DCZOG
DIK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBS
EJD
EMB
EMK
ESX
F5P
FDB
FIJ
FUBAC
G-S
GODZA
HZ~
IHE
IPNFZ
IX1
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
M41
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P4E
PQQKQ
ROL
SUPJJ
SV3
TEORI
TR2
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WVDHM
WYJ
ZZTAW
AAYWO
AAYXX
ACVFH
ADCNI
AEUPX
AFPUW
AGCQF
AIGII
AKBMS
AKYEP
APXCP
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c3887-2191115892ae6acc490e53ccf59ded501d3ebcdf32997e26ace7c234cfd10863
IEDL.DBID DR2
ISSN 1538-7933
1538-7836
IngestDate Fri Jul 11 10:12:57 EDT 2025
Wed Aug 13 10:32:24 EDT 2025
Mon Jul 21 05:51:40 EDT 2025
Tue Jul 01 00:27:09 EDT 2025
Thu Apr 24 23:00:06 EDT 2025
Wed Jan 22 16:24:33 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords von Willebrand disease
ABO blood-group system
blood group antigens
von Willebrand factor
type 3 VWD
Language English
License 2015 International Society on Thrombosis and Haemostasis.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3887-2191115892ae6acc490e53ccf59ded501d3ebcdf32997e26ace7c234cfd10863
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink http://www.jthjournal.org/article/S153878362208401X/pdf
PMID 25650553
PQID 1667755665
PQPubID 1086376
PageCount 9
ParticipantIDs proquest_miscellaneous_1669447558
proquest_journals_1667755665
pubmed_primary_25650553
crossref_primary_10_1111_jth_12867
crossref_citationtrail_10_1111_jth_12867
wiley_primary_10_1111_jth_12867_JTH12867
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2015
2015-04-00
2015-Apr
20150401
PublicationDateYYYYMMDD 2015-04-01
PublicationDate_xml – month: 04
  year: 2015
  text: April 2015
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Journal of thrombosis and haemostasis
PublicationTitleAlternate J Thromb Haemost
PublicationYear 2015
Publisher Elsevier Limited
Publisher_xml – name: Elsevier Limited
References 1973; 52
1992; 267
2005; 115
2013; 122
1983; 50
2006; 4
2013; 121
2004; 2
2007; 97
1998; 67
1977; 60
2001; 276
1987; 69
2010; 21
2006; 108
2004; 279
2013; 11
2006; 46
2000; 37
2005; 106
2002; 22
2009; 7
2007; 5
2003; 1
2008; 111
1985; 37
2012; 8
1996; 88
Orstavik (10.1111/jth.12867_bb0030) 1985; 37
Borchiellini (10.1111/jth.12867_bb0025) 1996; 88
O'Donnell (10.1111/jth.12867_bb0075) 2000; 37
Wolofsky (10.1111/jth.12867_bb0120) 2012; 8
Nossent (10.1111/jth.12867_bb0065) 2006; 4
Mannucci (10.1111/jth.12867_bb0150) 2013; 122
Sadler (10.1111/jth.12867_bb0010) 1998; 67
Nachman (10.1111/jth.12867_bb0020) 1977; 60
Varadi (10.1111/jth.12867_bb0125) 2009; 7
Lenting (10.1111/jth.12867_bb0105) 2004; 279
Haberichter (10.1111/jth.12867_bb0090) 2006; 108
McCallum (10.1111/jth.12867_bb0040) 1983; 50
Gallinaro (10.1111/jth.12867_bb0085) 2008; 111
Fan (10.1111/jth.12867_bb0115) 2010; 21
Yamamoto (10.1111/jth.12867_bb0110) 2001; 276
Eikenboom (10.1111/jth.12867_bb0070) 2013; 121
Jaffe (10.1111/jth.12867_bb0015) 1973; 52
O'Donnell (10.1111/jth.12867_bb0050) 2005; 106
Lethagen (10.1111/jth.12867_bb0100) 2007; 5
Casari (10.1111/jth.12867_bb0145) 2013; 11
Gill (10.1111/jth.12867_bb0140) 1987; 69
Jenkins (10.1111/jth.12867_bb0045) 2006; 46
O'Donnell (10.1111/jth.12867_bb0055) 2002; 22
Tjernberg (10.1111/jth.12867_bb0095) 2004; 2
Matsui (10.1111/jth.12867_bb0035) 1992; 267
Morelli (10.1111/jth.12867_bb0060) 2007; 97
Motto (10.1111/jth.12867_bb0130) 2005; 115
Brown (10.1111/jth.12867_bb0080) 2003; 1
Stoddart (10.1111/jth.12867_bb0135) 1996; 88
References_xml – volume: 111
  start-page: 3540
  year: 2008
  end-page: 5
  article-title: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor
  publication-title: Blood
– volume: 2
  start-page: 257
  year: 2004
  end-page: 65
  article-title: Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
  publication-title: J Thromb Haemost
– volume: 60
  start-page: 914
  year: 1977
  end-page: 21
  article-title: Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes
  publication-title: J Clin Invest
– volume: 67
  start-page: 395
  year: 1998
  end-page: 424
  article-title: Biochemistry and genetics of von Willebrand factor
  publication-title: Annu Rev Biochem
– volume: 122
  start-page: 648
  year: 2013
  end-page: 57
  article-title: Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma‐free method: a prospective clinical trial
  publication-title: Blood
– volume: 7
  start-page: 1134
  year: 2009
  end-page: 42
  article-title: Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor
  publication-title: J Thromb Haemost
– volume: 11
  start-page: 202
  year: 2013
  end-page: 11
  article-title: Clearance of von Willebrand factor
  publication-title: J Thromb Haemost
– volume: 88
  start-page: 1692
  year: 1996
  end-page: 9
  article-title: Clearance of normal and type 2A von Willebrand factor in the rat
  publication-title: Blood
– volume: 276
  start-page: 13701
  year: 2001
  end-page: 8
  article-title: Murine equivalent of the human histo‐blood group ABO gene is ‐AB gene and encodes a glycosyltransferase with both A and B transferase activity
  publication-title: J Biol Chem
– volume: 88
  start-page: 2951
  year: 1996
  end-page: 8
  article-title: Quantitative analysis of von Willebrand factor propeptide release effect of experimental endotoxemia and administration of 1‐deamino‐8‐D‐arginine vasopressin in humans
  publication-title: Blood
– volume: 279
  start-page: 12102
  year: 2004
  end-page: 9
  article-title: An experimental model to study the survival of von Willebrand factor
  publication-title: J Biol Chem
– volume: 46
  start-page: 1836
  year: 2006
  end-page: 44
  article-title: ABO blood group determines plasma von Willebrand factor levels: a biological function after all?
  publication-title: Transfusion
– volume: 22
  start-page: 335
  year: 2002
  end-page: 41
  article-title: Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 115
  start-page: 2752
  year: 2005
  end-page: 61
  article-title: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13‐deficient mice
  publication-title: J Clin Invest
– volume: 106
  start-page: 1988
  year: 2005
  end-page: 91
  article-title: Bombay phenotype is associated with reduced plasma‐VWF levels and an increased susceptibility to ADAMTS13 proteolysis
  publication-title: Blood
– volume: 37
  start-page: 540
  year: 2000
  end-page: 7
  article-title: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens
  publication-title: J Vasc Res
– volume: 21
  start-page: 877
  year: 2010
  end-page: 90
  article-title: Induction of human blood group A antigen expression on mouse cells, using lentiviral gene transduction
  publication-title: Hum Gene Ther
– volume: 52
  start-page: 2757
  year: 1973
  end-page: 64
  article-title: Synthesis of antihemophilic factor antigen by cultured human endothelial cells
  publication-title: J Clin Invest
– volume: 267
  start-page: 8723
  year: 1992
  end-page: 31
  article-title: Structures of the asparagine‐linked oligosaccharide chains of human von Willebrand factor
  publication-title: J Biol Chem
– volume: 97
  start-page: 534
  year: 2007
  end-page: 41
  article-title: ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens
  publication-title: Thromb Haemost
– volume: 69
  start-page: 1691
  year: 1987
  end-page: 5
  article-title: The effect of ABO blood group on the diagnosis of von Willebrand disease
  publication-title: Blood
– volume: 37
  start-page: 89
  year: 1985
  end-page: 101
  article-title: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level
  publication-title: Am J Hum Genet
– volume: 50
  start-page: 757
  year: 1983
  article-title: Factor VIII levels and blood group antigens
  publication-title: J Thromb Haemost
– volume: 4
  start-page: 2556
  year: 2006
  end-page: 62
  article-title: von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis
  publication-title: J Thromb Haemost
– volume: 1
  start-page: 1714
  year: 2003
  end-page: 17
  article-title: Increased clearance of von Willebrand factor antigen post‐DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
  publication-title: J Thromb Haemost
– volume: 108
  start-page: 3344
  year: 2006
  end-page: 51
  article-title: Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival
  publication-title: Blood
– volume: 8
  start-page: e1002942
  year: 2012
  article-title: ABO blood groups influence macrophage‐mediated phagocytosis of Plasmodium falciparum‐infected erythrocytes
  publication-title: PLoS Pathog
– volume: 121
  start-page: 2336
  year: 2013
  end-page: 9
  article-title: VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease
  publication-title: Blood
– volume: 5
  start-page: 1420
  year: 2007
  end-page: 30
  article-title: von Willebrand factor/factor VIII concentrate (Haemate  P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery
  publication-title: J Thromb Haemost
– volume: 108
  start-page: 3344
  year: 2006
  ident: 10.1111/jth.12867_bb0090
  article-title: Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival
  publication-title: Blood
  doi: 10.1182/blood-2006-04-015065
– volume: 115
  start-page: 2752
  year: 2005
  ident: 10.1111/jth.12867_bb0130
  article-title: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13‐deficient mice
  publication-title: J Clin Invest
  doi: 10.1172/JCI26007
– volume: 67
  start-page: 395
  year: 1998
  ident: 10.1111/jth.12867_bb0010
  article-title: Biochemistry and genetics of von Willebrand factor
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.biochem.67.1.395
– volume: 4
  start-page: 2556
  year: 2006
  ident: 10.1111/jth.12867_bb0065
  article-title: von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.02273.x
– volume: 69
  start-page: 1691
  year: 1987
  ident: 10.1111/jth.12867_bb0140
  article-title: The effect of ABO blood group on the diagnosis of von Willebrand disease
  publication-title: Blood
  doi: 10.1182/blood.V69.6.1691.1691
– volume: 276
  start-page: 13701
  year: 2001
  ident: 10.1111/jth.12867_bb0110
  article-title: Murine equivalent of the human histo‐blood group ABO gene is acis‐AB gene and encodes a glycosyltransferase with both A and B transferase activity
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M010805200
– volume: 122
  start-page: 648
  year: 2013
  ident: 10.1111/jth.12867_bb0150
  article-title: Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma‐free method: a prospective clinical trial
  publication-title: Blood
  doi: 10.1182/blood-2013-01-479527
– volume: 37
  start-page: 540
  year: 2000
  ident: 10.1111/jth.12867_bb0075
  article-title: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens
  publication-title: J Vasc Res
  doi: 10.1159/000054087
– volume: 106
  start-page: 1988
  year: 2005
  ident: 10.1111/jth.12867_bb0050
  article-title: Bombay phenotype is associated with reduced plasma‐VWF levels and an increased susceptibility to ADAMTS13 proteolysis
  publication-title: Blood
  doi: 10.1182/blood-2005-02-0792
– volume: 279
  start-page: 12102
  year: 2004
  ident: 10.1111/jth.12867_bb0105
  article-title: An experimental model to study the in vivo survival of von Willebrand factor
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M310436200
– volume: 46
  start-page: 1836
  year: 2006
  ident: 10.1111/jth.12867_bb0045
  article-title: ABO blood group determines plasma von Willebrand factor levels: a biological function after all?
  publication-title: Transfusion
  doi: 10.1111/j.1537-2995.2006.00975.x
– volume: 2
  start-page: 257
  year: 2004
  ident: 10.1111/jth.12867_bb0095
  article-title: Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2003.00435.x
– volume: 52
  start-page: 2757
  year: 1973
  ident: 10.1111/jth.12867_bb0015
  article-title: Synthesis of antihemophilic factor antigen by cultured human endothelial cells
  publication-title: J Clin Invest
  doi: 10.1172/JCI107471
– volume: 22
  start-page: 335
  year: 2002
  ident: 10.1111/jth.12867_bb0055
  article-title: Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/hq0202.103997
– volume: 1
  start-page: 1714
  year: 2003
  ident: 10.1111/jth.12867_bb0080
  article-title: Increased clearance of von Willebrand factor antigen post‐DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
  publication-title: J Thromb Haemost
  doi: 10.1046/j.1538-7836.2003.00359.x
– volume: 97
  start-page: 534
  year: 2007
  ident: 10.1111/jth.12867_bb0060
  article-title: ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens
  publication-title: Thromb Haemost
  doi: 10.1160/TH06-09-0549
– volume: 21
  start-page: 877
  year: 2010
  ident: 10.1111/jth.12867_bb0115
  article-title: Induction of human blood group A antigen expression on mouse cells, using lentiviral gene transduction
  publication-title: Hum Gene Ther
  doi: 10.1089/hum.2008.089
– volume: 37
  start-page: 89
  year: 1985
  ident: 10.1111/jth.12867_bb0030
  article-title: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level
  publication-title: Am J Hum Genet
– volume: 50
  start-page: 757
  year: 1983
  ident: 10.1111/jth.12867_bb0040
  article-title: Factor VIII levels and blood group antigens
  publication-title: J Thromb Haemost
  doi: 10.1055/s-0038-1665305
– volume: 5
  start-page: 1420
  year: 2007
  ident: 10.1111/jth.12867_bb0100
  article-title: von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2007.02588.x
– volume: 267
  start-page: 8723
  year: 1992
  ident: 10.1111/jth.12867_bb0035
  article-title: Structures of the asparagine‐linked oligosaccharide chains of human von Willebrand factor
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)50338-6
– volume: 60
  start-page: 914
  year: 1977
  ident: 10.1111/jth.12867_bb0020
  article-title: Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes
  publication-title: J Clin Invest
  doi: 10.1172/JCI108846
– volume: 8
  start-page: e1002942
  year: 2012
  ident: 10.1111/jth.12867_bb0120
  article-title: ABO blood groups influence macrophage‐mediated phagocytosis of Plasmodium falciparum‐infected erythrocytes
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1002942
– volume: 11
  start-page: 202
  year: 2013
  ident: 10.1111/jth.12867_bb0145
  article-title: Clearance of von Willebrand factor
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12226
– volume: 121
  start-page: 2336
  year: 2013
  ident: 10.1111/jth.12867_bb0070
  article-title: VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease
  publication-title: Blood
  doi: 10.1182/blood-2012-09-455089
– volume: 88
  start-page: 1692
  year: 1996
  ident: 10.1111/jth.12867_bb0135
  article-title: Clearance of normal and type 2A von Willebrand factor in the rat
  publication-title: Blood
  doi: 10.1182/blood.V88.5.1692.1692
– volume: 111
  start-page: 3540
  year: 2008
  ident: 10.1111/jth.12867_bb0085
  article-title: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor
  publication-title: Blood
  doi: 10.1182/blood-2007-11-122945
– volume: 88
  start-page: 2951
  year: 1996
  ident: 10.1111/jth.12867_bb0025
  article-title: Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1‐deamino‐8‐D‐arginine vasopressin in humans
  publication-title: Blood
  doi: 10.1182/blood.V88.8.2951.bloodjournal8882951
– volume: 7
  start-page: 1134
  year: 2009
  ident: 10.1111/jth.12867_bb0125
  article-title: Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2009.03453.x
SSID ssj0019520
Score 2.2322142
Snippet Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O...
One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower...
Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O...
One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 592
SubjectTerms ABO Blood-Group System - blood
ABO blood‐group system
Animals
Biomarkers - blood
blood group antigens
Drug Combinations
Factor VIII - administration & dosage
Female
Humans
Infusions, Intravenous
Male
Mice, Inbred C57BL
Mice, Knockout
Protein Binding
Time Factors
type 3 VWD
von Willebrand disease
von Willebrand Disease, Type 3 - blood
von Willebrand Disease, Type 3 - diagnosis
von Willebrand Disease, Type 3 - drug therapy
von Willebrand factor
von Willebrand Factor - administration & dosage
von Willebrand Factor - genetics
von Willebrand Factor - metabolism
Title No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjth.12867
https://www.ncbi.nlm.nih.gov/pubmed/25650553
https://www.proquest.com/docview/1667755665
https://www.proquest.com/docview/1669447558
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB1CDiGXNmn6sWlSpqWQXrysLUte0VNSGpZAcigbyCFgJFkm0GKXrDeH_PrOSLZp0hRKbwaPkGzNaJ40ozcAH72Z5Z7JB72ufZKreZpoK4okc2pmrbZpZfii8PmFWlzmZ1fyagM-D3dhIj_EeODGlhHWazZwY1e_G3l3M6XFVfFNcs7VYkD0baSOSrUMlIzBoEkHRc8qFLJ4hpYPfdEfAPMhXg0O5_Q5XA9DjXkm36frzk7d_SMWx__8lh141gNRPI6aswsbvnkBW-d9qH0P7i5a9H3JUSRkiwaj-8OYAoJtjXdtg3xgw8HnpsJYu-dohccnCwwZ8RgujSDNHpN-rpDkn2yDjqtXsAK-hOXp1-WXRdIXaUic4AWKVjz6BjnXmfHKOJfrmZfCuVrqyldyllbCW1fVgvxe4TMS8YXLRO7qios8iVew2bSNfwNoZZWTH6UNmnC5SY2urcqs4FiytKnSE_g0zFbpegJzrqPxoxw3Mt1NGX7jBD6Moj8ja8dTQgfDlJe94a7KVKmikIRx5QTej6_J5DiOYhrfroOMZp5EOZ_A66gqYy-EIAlTSkGDDRP-9-7Ls-UiPOz_u-hb2CbAJmPm0AFsdrdrf0igqLPvgvb_ArsoB2c
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VIgEXyldhocCAkOCS1SaOnbXUSwtUoXT3gBapFxTFjqNKoASx2R749czYSdRCkRC3SBnLTsYz82yP3wC8cuUsdUw-6HTtolTN40gbkUWJVTNjtImrki8KL5Yq_5wen8rTLdgf7sIEfohxw40tw_trNnDekL5o5d3ZlLyryq7Bda7ozcz57z6N5FGxlp6U0Zs0zULR8wr5PJ6h6eVo9AfEvIxYfcg52oEvw2BDpsnX6aYzU_vzNx7H__2aO3C7x6J4ECbPXdhyzT24sehP2-_D-bJF11cdRQK3WGKIgBiyQLCt8bxtkPds-Py5qTCU73m9xoPDHH1SPPp7I0gKZN7PNZL8lW3QcgELnoMPYHX0fvU2j_o6DZEV7KPI6dE3yLlOSqdKa1M9c1JYW0tduUrO4ko4Y6taUOjLXEIiLrOJSG1dcZ0nsQvbTdu4R4BGVimFUlqjCZuWcalroxIj-DhZmljpCbwZ1FXYnsOcS2l8K8a1THdW-N84gZej6PdA3HGV0N6g86K33XURK5VlkmCunMCL8TVZHR-llI1rN15GM1WinE_gYZgrYy8EIglWSkGD9Rr_e_fF8Sr3D4__XfQ53MxXi5Pi5MPy4xO4RfhNhkSiPdjufmzcU8JInXnmTeEXKRwLgw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qheJL_W6vrToVQV9yJNns5hafqvU4a3uInNAHIWQ_QqElKb1cH_zrO7ubBKsVxLdAZtlNZmfmt7uzvwF4Y8s4s4580MrKRpmYJJFULI9SLWKlpEpM6S4Kn8zF7Ht2dMpP1-B9fxcm8EMMG27OMry_dgZ-aapfjbw9G5NzFfk9uJ-JWLq6DYffBu6oRHLPyegtmiYh62iFfBpP3_R2MPoDYd4GrD7iTB_Cj36sIdHkfLxq1Vj__I3G8T8_5hFsdkgUD8LUeQxrtn4CGyfdWftTuJ43aLuao0jQFksM8Q9DDgg2FV43NbodG3f6XBsMxXveLvHgwwx9Sjz6WyNI6nOsn0sk-TvboHblK9wMfAaL6afFx1nUVWmINHMeilwefQOfyLS0otQ6k7HlTOuKS2MNjxPDrNKmYhT4cpuSiM11yjJdGVfliT2H9bqp7Tag4iajQEorNKazMillpUSqmDtM5ioRcgTvem0VumMwd4U0LophJdOeFf43juD1IHoZaDvuEtrrVV50lrssEiHynBPI5SPYH16TzbmDlLK2zcrLSEeUyCcj2ApTZeiFICSBSs5osF7hf---OFrM_MPOv4u-go2vh9Pi-PP8yy48IPDGQxbRHqy3Vyv7ggBSq156Q7gBAEcKMg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=No+evidence+for+a+direct+effect+of+von+Willebrand+factor%27s+ABH+blood+group+antigens+on+von+Willebrand+factor+clearance&rft.jtitle=Journal+of+thrombosis+and+haemostasis&rft.au=Groeneveld%2C+D.+J.&rft.au=Bekkum%2C+T.&rft.au=Cheung%2C+K.+L.&rft.au=Dirven%2C+R.+J.&rft.date=2015-04-01&rft.issn=1538-7933&rft.eissn=1538-7836&rft.volume=13&rft.issue=4&rft.spage=592&rft.epage=600&rft_id=info:doi/10.1111%2Fjth.12867&rft.externalDBID=10.1111%252Fjth.12867&rft.externalDocID=JTH12867
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7933&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7933&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7933&client=summon